SUBJECT INDEX

Abecarnil 762, 764
Acetylcholine
  cognitive function 182
  ethanol and release of 107
  modulation of NMDA receptors 977–984
α_1-Acid glycoprotein, in depression 505
Acute phase plasma proteins, melancholia 501–515
Adenosine-3′,5′-monophosphate, NGF withdrawal and neuronal degeneration 101
Adenylate cyclase, postnatal development 584
Adjustment disorders, beta-blockers 22
Adolescents
  lithium in mood and substance dependency 281–299
  sleep–wake schedule disorders 535
α_1-Adrenergic receptor, mediated PI hydrolysis, effect of stress 561–570
Adrenocorticotropic hormone
  depression, RU486 913–918
  5-HT_{1A} receptor functioning 657
Affective disorders
  carbamazepine + lithium 483–493
  phenylethylamine and noradrenergic function 45, 50
  stress in induction of 562
Age
  cholecystokinin receptor binding in brain 369–375
  neurotransmitters in dementia 883–890
  parvalbumin immunoreactivity in neocortex 332
  pharmacokinetics 302
  sleep and depression 313
Aggression
  5-HT 847–870
  pharmacological manipulation 1–7
  prenatal benzodiazepine exposure 597
  rodent models 847–870
    maternal 851, 858
    resident intruder 855
AIDS 145–170
  animal models 150
  brain–immune system interactions 154
  mechanisms of neuropathogenesis 147
  stress and immune function 160
Akathisia, neuroleptic induced 27–37
  effect of ritanserin 247–251
  role of iron 650
Alcohol, aggression 3
Alcoholism, cigarette smoking 108, 113
Alcohol withdrawal, drug treatment of anxiety 87–93
Alprazolam, social phobia 642
Alzheimer's disease 182
  cytoskeletal changes 317–328
  neurotransmitter changes 883–890
  nicotine as a cognitive enhancer 188
Amitriptyline, effect on 5-HT_{1A} receptor in brain 343, 346
Amphetamine
  behaviour development in mice 589
  evoked behaviours, role of cholinergic system 223–235
  noradrenergic blocking drugs and behaviour 985–1001
  quinine antinociception 354
Analgesia, quinine, effect of dopaminergic agents 351–360
Animal models
  aggressive behaviour 847–870
  AIDS and HIV encephalopathy 150
  cognitive enhancers 389–396
Anticholinergic agents, treatment of neuroleptic malignant syndrome 431, 435
Anticonvulsants, treatment of mania 691
Antidepressants
  dysthymia 933–941
  gepirone 271–280
  geriatric patients 301
  5-HT receptors 343, 346, 655–659
  long-term potentiation 717
  schizophrenia 517–528
    dysphoric patients 539–547
  social phobia 639
Antiepileptic drugs, clinical trials 79–85
Antihistaminic agents, neuroleptic malignant syndrome 435
Antinociception, quinine, dopaminergic mechanism 351–360
α_1-Antitrypsin, in depression 505
Anxiety
  in alcohol withdrawal, drug treatment 87–93
  beta-blockers 17–26
  flupenthixol decanoate 681, 683
  herbal medicine 172
  low dose neuroleptanxiolysis 135–143
  social phobia 635–646
Anxiolytics
  beta-blockers 17–26
  5-HT_{1A} receptor agonists 833–845
Apomorphine
  evoked behaviours, role of cholinergic system 223–235
  noradrenergic blocking drugs and behaviour 985–1001
Aryl-piperazine derivatives, anxiolytic activity 835, 838
Atenolol, social phobia 640

Athletic performance, zopiclone 55–63
Atropine, inositol phosphate accumulation in cultured neurons 417, 419
Attention, nicotine 183
  Alzheimer's disease 188
Autoimmune disease, CRH 550, 558

Baclofen
  anxiety in ethanol withdrawal 89, 91
  effect on GABA receptor 575
Basket neurons, parvalbumin immunoreactivity 329–337
Benserazide, quinine antinociception 354
Benzodiazepine receptors
  age-dependency 369–375
  new ligands 759–781
  pharmacophore for 773
  subtypes 758
Benzodiazepines
  affinity for receptors 759
  anxiety in ethanol withdrawal 87, 89
  anxiolytic activity 834–843
  behavioural development after prenatal exposure 587–604
  international regulation 9–16
  neuroleptic malignant syndrome 434, 436
  effect on SCH23390 binding *in vivo* 783–789
  social phobia 640, 642
Benztropine, neuroleptic malignant syndrome 433, 435
Beta-blockers
  anxiety disorders 17–26
    stress 20
  social phobia 641
Bicuculline, effect on brain neuropeptides 747–753
Blood pressure, tobacco smoking 474, 476
Borna virus, neurological damage 151
Brofaromine, social phobia 641
Bromazepam, anxiolytic effect 137
Bromocriptine, neuroleptic malignant syndrome 434, 435
Buspirone
  aggression 855, 862
  antidepressant activity 277
  anxiolytic activity 836
  social phobia 642

Calcium
  ethanol withdrawal 87
  muscarinic control in neuronal cells 253–270
Calcium currents, tetrodotoxin-sensitive, in CNS neurons 943–957
Cannabis abuse, imipramine for dysphoric schizophrenic patients 539–547
Captopril, learning and memory 119
Carbachol
  calcium in neuroblastoma cells 255
  PI turnover in cultured neurons 417
  stimulated PI hydrolysis, effect of stress 564
Carbamazepine
  affective disorders 483–493
  GABA receptor alterations 571–579
β-Carbolines, benzodiazepine receptor ligands 762
Carbon monoxide, tobacco smoking 474, 478
Cat, noradrenergic blocking drugs and behaviour 985–1001
Catecholaminergic neurons, cultured, effect of interleukin-6 623
Cathinone, shortening of place conditioning 969–976
Cationic lipids, gene transfer into neurons 959–968
Cell culture
  chromaffin cells 961
  CNS neurons 618, 960
  HIV-associated neural damage 147
Cerebellar granule cells, muscarinic responsiveness 262
Cerebral blood flow, schizophrenia 447
Ceruletide, tardive dystonia 127–134
c-*fos*, induction by NGF withdrawal 97, 101, 103
CGS8216 767, 775
CGS9896 767, 775
Chandelier neuron, parvalbumin immunoreactivity 329–337
Chloramphenicol acetyltransferase, gene transfer in neurons 962
Chlordiazepoxide, anxiety in ethanol withdrawal 89
Chlorpromazine, glucose metabolism in schizophrenia 873, 875
Cholecystokinin peptides, tardive dystonia 128
Cholecystokinin receptors, brain, age-dependency 369–375
Choline, effect on field potentials 401
Choline acetyltransferase, Alzheimer-type dementia 885
Cholinergic neurons, cultured, effect of neurotrophic factors 621
Cholinergic system
  Alzheimer-type dementia 883–889
  depression, REM induction with RS86 311–316
  information processing 182
  nicotine and ethanol 111
  role in behaviours evoked by apomorphine and amphetamine 223–235
Choto alkaloids 175, 176
Choto-San, headache 177
Chromaffin cells, gene transfer 961, 965
Chronotherapy, sleep–wake schedule disorders 530–536
Cigarette smoking
  alcohol consumption 108
  memory 186
  topographic EEG 463–482
Circadian rhythm, neuroleptic-induced akathisia 32
Clonidine, social phobia 642
Clozapine
  down-regulation of 5-HT_{1C} receptors in brain 727–732

glucose metabolism in schizophrenia 873
negative symptoms of schizophrenia 808
Cocaine-induced sensitization 237–246, 1003–1012
Cognitive enhancers
animal experiments for evaluation of 389–396
nicotine 181–191
Cognitive functioning, glycosaminoglycan polysulfate in old age dementias 661–676
Combination therapy, carbamazepine + lithium in affective disorders 483–493
Comorbidity, lithium 292
Complement component 4, in depression 505
Conditioned place preference, shortening 969–976
Continuous Performance Test, vulnerability to schizophrenia 706, 708, 711
Convulsants, effect on brain neuropeptides 747–753
Corpus callosum, schizophrenia 447
Corticotropin releasing hormone
behavioural responses in LEW/N and F344/N rats 549–560
binding in brain, postnatal development 581–586
Cortisol
in depression 70
RU486 913–918
5-HT_{1A} receptor functioning 657
postnatal mood changes 609, 927–930
C-reactive protein, in depression 506
Cyclopyrrolones, benzodiazepine receptor ligands 765
Cyclothymia, valproate treatment 692
Cytoskeletal protein, Alzheimer's disease 317–328

Dantrolene sodium, neuroleptic malignant syndrome 434, 436
Degeneration, NGF deprivation 95–106
Delayed sleep phase syndrome 529
chronotherapy 530–536
Dementia
elderly, glycosaminoglycan polysulfate 661–676
neurotransmitter changes 883–890
Depression
acute phase plasma proteins 501–515
biological markers 791–796
ECT effect on TSH response to TRH 495–500
elderly, nortriptyline 301–309
flupenthixol decanoate 681, 682
gepirone 271–280
glucocorticoid receptor binding 65–78
neuroendocrine markers of 5-HT 655–659
neuroleptic-induced akathisia 31
oriental medicine 171–180
β-phenylethylamine in plasma 43–53
postnatal 605–615, 921–932
REM induction with RS86 311–316
RU486 913–920
serotonergic antidepressants in dysthymia 933–941
Desipramine, effect on 5-HT_{1A} receptor in brain 343, 346
Development
behavioural changes after prenatal benzodiazepine exposure 587–604
CRF binding in brain 581–586
neurons in culture 617–633
parvalbumin immunoreactivity in axon terminals 332
Dexamethasone, receptor binding in depression 69–75
Dexamethasone suppression test, depression 791, 792
Diazepam
antagonism of phencyclidine agonist effects on dopamine metabolism 211–215
neuroleptic malignant syndrome 437
6,7-Dimethoxy-4-ethyl, methyl ester 759, 762
1-(2,5-Dimethoxy-4-iodophenyl)-2-amino propane, effect on aggression 858
Diphenhydramine, neuroleptic malignant syndrome 435
Disulfiram, effect on apomorphine and amphetamine evoked behaviours 985–1001
DN2327 767
L-DOPA, quinine antinociception 354
Dopamine
cocaine-induced sensitization 237–246, 1003–1012
in hippocampal slices, effects of lithium, sodium and choline 406
involvement in gastrointestinal injury 217–221
metabolism in brain, effects of diazepam and phencyclidine agonists 211–215
neuroleptic malignant syndrome 427
nucleus accumbens and sensitization to drugs of abuse 237–246, 1003–1012
quinine antinociception 351–360
schizophrenia 204, 206, 799, 802
social phobia 639
Dopamine agonists, neuroleptic malignant syndrome 434, 435
Dopamine hydrochloride, neuroleptic malignant syndrome treatment 437
Dopamine D1 receptors
role in gastrointestinal injury 217–221
schizophrenia 806–819
sedative drugs and receptor binding *in vivo* 783–789
tardive dystonia 131
Dopamine D2 receptors, neuroleptics and glucose metabolism in schizophrenia 872
Doxepin, effect on 5-HT_{1A} receptor in brain 343, 346
Drinking, schizophrenia 39–44
Duodenal ulcer, central dopamine involvement 217–221
Dysthymia, serotonergic antidepressants 933–941

Elderly
dementia, glycosaminoglycan polysulfate 661–676
depression, nortriptyline 301–309

Electroconvulsive treatment
effect on dystonic movement 131
neuropeptides in brain 747
TSH response to TRH in depression 495–500
Electroencephalogram mapping
schizophrenia 451–460
tobacco smoking 463–482
Electroretinogram, lithium and photoreceptor G protein 738
Elevated plus-maze, learning and memory 117–125
Eltoprazine, effect on aggression 855, 858, 862
β-Endorphin, postnatal depression 610
Epilepsy, zonisamide 79–85
Esophageal functional stenosis, herbal medicine 179
Estrogen
noradrenaline neurons in brain 380
postnatal mood changes 608
Ethanol
alteration of nicotine action 107–115
effect on SCH23390 binding in brain 783–789
treatment of anxiety after withdrawal 87–93
Ethnicity, haloperidol metabolism 193–202
Event-related potentials
menstrual cycle 901–911
nicotine 185
Exhausted depression, herbal medicine 178
Extrapyramidal symptoms, neuroleptic malignant syndrome 431, 434, 438

Fenfluramine, prolactin response 656
FG8205 759
Fibroblasts
cytoskeletal change in Alzheimer's disease 317–328
glucocorticoid receptor binding in depression 73
Fluid intake, schizophrenia 39–44
Flumazenil
anxiety in ethanol withdrawal 89
SCH23390 binding in brain 783–789
Flunitrazepam, SCH23390 binding in brain 783–789
Fluoxetine, dysthymia 936–939
Flupenthixol decanoate, depression and psychosomatic disorders 677–689
Fluphenazine, glucose metabolism in schizophrenia 873
Fluspirilene, anxiolytic effect 135–143
Fluvoxamine, effect on aggression 858
Fodrin, in Alzheimer's disease fibroblasts 322, 324, 326
Fostering, benzodiazepines 596

GABA, valproate treatment of mania 692, 697
$GABA_B$ receptors
ethanol withdrawal 87
lithium, carbamazepine and valproate 571–579
Gastric ulcer, central dopamine involvement 217–221
Gene transfer, neurons 959–968
Gepirone
antidepressant activity 271–280
cortisol response in depression 658
Gerbils, evaluation of cognitive enhancers 389–396
Geriatric depression, nortriptyline 301–309
Glucocorticoid, immune response, AIDS 154, 164
Glucocorticoid receptors
brain and immune system, AIDS 160
depression 65–78
Glucose, regional metabolism in schizophrenia, effect of neuroleptics 871–881
Glutaminergic transmission, effect of acetylcholine 977–984
Glycosaminoglycan polysulfate, dementia in the elderly 661–676
G-protein
photoreceptors, effect of lithium 733–745
PI turnover in muscarinic receptors in cultured neurons 420
G_i protein, 5-HT_{1A} receptor interaction 344
Grand mal seizures, neuropeptides in brain 747–753
Guanosine-3′,5′-monophosphate, hydrolysis in photoreceptor cell, effect of lithium 738

Haloperidol
glucose metabolism in schizophrenia 873, 875
5-HT_{1C} receptors and dopamine D2 receptors 729
metabolism, ethnicity 193–202
Hange-Koboku, esophageal functional stenosis 179
Haptoglobin, in depression 505
Headache, Choto-San 177
Heart rate, tobacco smoking 465, 474, 476
Herbal medicines, depression 171–180
Herpes simplex virus-1, behavioural disorders 150
Hippocampus
acute effects of lithium *in vitro* 397–412
cholecystokinin receptors 371
GABA receptors, mood stabilizers 571–579
oxaprotiline and long-term potentiation 717–725
tetrodotoxin-sensitive Ca^{2+} current 943–957
HIV
animal models of encephalopathy 150
brain–immune system interactions 154
mechanisms of neuropathogenesis 147
stress and immune function 160
HIV-1-associated peptides, immunoregulatory activity 149
Hochu-Ekki, depression 178
Homovanillic acid
in brain
Alzheimer-type dementia 887
effect of diazepam, phencyclidine and MK-801 213
in plasma, schizophrenia, effect of mianserin 521, 523
Hormones, role in postnatal mood changes 608
Hospitalization, carbamazepine + lithium in affective disorders 486, 491

8-Hydroxy-2-(di-*n*-propylamino)tetralin, effect on aggression 855, 857, 858, 862
6-Hydroxydopamine, lesions 804
5-Hydroxyindoleacetic acid
  Alzheimer-type dementia 885, 886
  schizophrenia, effect of mianserin 521, 523
Hydroxyquinolines, benzodiazepine receptor ligands 765
5-Hydroxytryptamine
  aggression 847–870
  Alzheimer-type dementia 885, 886
  depression 340
    neuroendocrine markers 655–659
  dopamine D1 regulation and negative symptoms of schizophrenia 816
  dysthymia 934
  hippocampal slices, effect of lithium, sodium and choline 406
  postnatal depression 611
  stimulated PI hydrolysis, effect of stress 564
5-Hydroxytryptamine 1A receptors
  effect of islet-activating protein and antidepressants 339–349
  neuroendocrine markers 657
5-Hydroxytryptamine 1A receptor agonists
  aggression 585, 862
  anxiolytic activity 833–845
  depression 271–280
5-Hydroxytryptamine 1B receptor agonist, behavioural tolerance 361–368
5-Hydroxytryptamine 1C receptor, down-regulation by clozapine 727–732
5-Hydroxytryptamine 2 receptor
  herbal medicines 174
  mediated PI hydrolysis, effect of stress 561–570
5-Hydroxytryptamine 2 receptor antagonist, neuroleptic-induced akathisia 247–251
Hypernychthemeral syndrome 529, 534
Hyperpyrexia, neuroleptic malignant syndrome 427, 430, 434
Hyponatremia, schizophrenia 39
Hypnotics, zopiclone, athletic performance 55
Hypothalamic–pituitary–adrenal axis
  behavioural responses in LEW/N and F344/N rats 550, 554
  depression 913, 919
  immune response 154, 156
  role in susceptibility to inflammatory disease 158
Hypothermia, nicotine induced, effect of ethanol 110

ICI 190, 622, 769
Imidazobenzothiazoles, benzodiazepine receptor ligands 763
Imidazopyrimidines, benzodiazepine receptor ligands 771
Imidazoquinolines, benzodiazepine receptor ligands 771
Imipramine
  dysphoric schizophrenic patients 539–547
  5-HT_{1A} receptor in brain 343, 346
  platelet binding in depression 793, 794
Immune system
  brain interactions, AIDS 154
  corticotropin releasing hormone 549
  depression 501
  neurotransmission with cells of 159
  stress, AIDS 160
Immunotoxin, T-cell death 149
Impulsiveness, pharmacological manipulation 1–7
Inflammatory disease, HPA axis in susceptibility 158
Inflammatory response, depression 501, 509
Inositol phosphate
  accumulation in brain, effect of stress 561–570
  calcium mobilization 258, 260
Interleukin-1
  immune response 155, 158
  melanotropins and effects in brain 157
Interleukin-1β, in depression 508, 509
Interleukin-6
  effect on cultured neurons 622
  in depression 508
Ipsapirone
  aggression 855, 862
  anxiolytic activity 838
Iron, neuroleptic-induced movement disorders 647–653
Ischaemia, animal model of dementia 394
Islet-activating protein, 5-HT_{1A} receptors in brain 339–349
Isolation, tolerance to 1,3-(trifluoromethyl)phenylpiperazine 362, 365

Learning, elevated plus-maze 117–125
Leukocytes, glucocorticoid receptor binding in depression 71
Light, lithium and photoreceptor G-proteins 734, 736, 738
Lipopolyamines, gene transfer into neurons 960
Lithium
  acute effects in hippocampal slices 397–412
  + carbamazepine, affective disorders 483–493
  GABA receptor alterations 571–579
  mood and substance dependency 281–299
  photoreceptor G-protein 733–745
Locomotor activity
  cocaine sensitization 1003, 1007
  neuroleptic-induced akathisia 31
  prenatal benzodiazepine exposure 593–598
  scopolamine effect on apomorphine and amphetamine induced changes 226–234
  shortening conditioned place preference 972–974
Long-term potentiation, oxaprotiline 717–725
Lorazepam, neuroleptic malignant syndrome 437
Lymphocytes
  HIV-1 146
  immune response 154

α_2-Macroglobulin, in depression 505
Macrophages
  interleukin-1 mediated immunoregulation 158
  quinolinic acid induced CNS damage in AIDS 148
Magnetic resonance imaging
  schizophrenia 447
  tardive dyskinesia 650
Major depression, glucocorticoid receptor binding 65–78
Mania
  neuroleptic-induced akathisia 31
  valproate 691–701
Maternal aggression 850, 858
Maternal behaviour, benzodiazepines 595
Melancholia, acute phase plasma proteins 501–505
Melanotropin receptors, in brain 157
Melanotropins, modulation of interleukin-1 effects in brain 156, 157
Memory
  elevated plus-maze 117–125
  nicotine 186
Menstrual cycle
  event-related potentials 901–911
  psychiatric disorders 383
Mesolimbic dopamine
  role in stress-induced gastric lesions 220
  sensitization to drugs of abuse 237–246
3-Methoxy-4-hydroxyphenylglycol
  depression 47–50
    effect of ECT 497, 498
  schizophrenia, effect of mianserin 521, 523
N-Methyl-D-aspartate receptors
  learning and memory 123
  modulation by acetylcholine 977–984
N-Methyl piperidil benzylate, binding in brain, effect of sedative drugs 785
α-Methyl-*p*-tyrosine, quinine antinociception 354
MHC I-a expression, restraint stress 161
Mianserin, schizophrenia 517–528
MK-801
  increased brain HVA, effect of diazepam 213
  learning and memory 119–123
Moclobemide, social phobia 641
Modality shift, vulnerability to schizophrenia 705, 706
Monkey
  parvalbumin immunoreactivity in neocortex 329–337
  SIV models for HIV-1 infection 152
Monoamine metabolites, schizophrenia, effect of mianserin 521, 523, 524
Monoamine oxidase inhibitors, social phobia 639, 640
Monoaminergic systems, changes after prenatal benzodiazepine exposure 591
Monoamines, in hippocampal slices, effect of lithium 406
Monocytosis, depression 509
Mood, postpartum 607
Mood disorder, adolescents, lithium 288
Mood stabilizers, GABA receptors in hippocampus 571–579
Morphine, developmental profile of response after oxazepam 592
Motor cortex, parvalbumin immunoreactivity 333
Motor function, schizophrenia, PET-EEG 449, 452
Muscarinic receptors
  PI metabolism and intracellular calcium 253–270
  PI metabolism and stress 561–570
  PI turnover and up-regulation of 413–424
  sedative drugs and receptor binding in brain 785

Negative symptoms, schizophrenia 798
Nerve growth factor
  effect on cultured neurons 621
  PC12 cell death following withdrawal 95–106
Neural cres-derived post mitotic cells, genetic analyses 959–968
Neuroblastoma cells, second messenger responses 253–270
Neurokinin A, brain regional distribution, chemical convulsants 747–753
Neuroleptanxiolysis, in anxiety states 135–143
Neuroleptic-induced akathisia, effect of ritanserin 247–251
Neuroleptic-induced movement disorders, body iron status 647–653
Neuroleptic malignant syndrome 425–443
  diagnosis 428
  drugs and recommended dosage 435
  role of iron 651
  treatment 430
Neuroleptics
  induced akathisia, psychomotor activity 27–37
  induced tardive dystonia, ceruletide treatment 127
  low dose, anxiety and depression 677
  schizophrenia 799
    early serum levels and therapeutic response 891–900
    regional glucose metabolism 871–881
Neuronal cells, culture, neurotrophic factors 617–633
Neuronal degeneration, NGF withdrawal 95–106
Neuronal excitability, lithium 398, 401
Neurons
  Ca^{2+} currents 943–957
  cultured, PI turnover and up-regulation of muscarinic receptors 413–424
  genetic analysis 959–968
Neuropeptides, effect of convulsants 747–753
Neuropeptide Y, brain regional distribution, chemical convulsants 747–753
Neurotensin, brain regional distribution, chemical convulsants 747–753
Neurotransmitters, Alzheimer-type dementia 883–890

Neurotrophic factors, effect on cultured neurons 621–628
Nicotine
cognitive enhancer 181–191
EEG 474, 477
ethanol alters hypothermic response 107–115
Nightmare, herbal medicine 174
Nitrendipine, anxiety in alcohol withdrawal 87, 89, 92
Nootropics, learning and memory 119
Noradrenaline
action of sex hormones 377–388
Alzheimer-type dementia 887
apomorphine and amphetamine evoked behaviours 985–1001
depression, β-phenylethylamine 45–53
dopamine D1 regulation and negative symptoms of schizophrenia 814
hippocampal slices, effects of lithium, sodium and choline 406
immune response 159
stimulated PI hydrolysis, effect of stress 564
Nortriptyline, depressed elderly 301–309
Nucleus accumbens
cocaine-induced sensitization 237–246, 1004, 1006
dopamine hypoactivity, schizophrenia 810
Nucleus basalis of Meynert, modulation of NMDA receptors by acetylcholine 977–984

Offensive behaviour, models 847, 855
Oriental medicine, depression 171–180
Oxaprotiline, long-term potentiation 717–725
Oxazepam, postnatal behavioural changes 593–598

Pain
dopamine 352, 355
flupenthixol decanoate 681, 685, 686
induced aggression 851
Panic disorder
beta-blockers 24
social phobia 639
Pargyline, quinine antinociception 354
Parkinsonism, drug-induced, role of iron 650
Parvalbumin, immunoreactivity in axon terminals 329–337
PC12 cells, neuronal degeneration caused by NGF deprivation 95–106
Pentobarbital, SCH23390 binding in brain 783–789
Pentylene tetrazole, brain neuropeptides 747–753
Perazine, early serum levels and therapeutic response in schizophrenia 891–900
Pertussis toxin
cocaine-induced sensitization in nucleus accumbens 241
mesocorticolimbic dopamine system 1006–1010
Pharmacophore, benzodiazepine receptors 773
Phencyclidine, dopamine metabolism, diazepam effects 211–215
Phenelzine, social phobia 640
Phenoxybenzamine, apomorphine and amphetamine evoked behaviours 985–1001
β-Phenylethylamine, noradrenergic function in depression 45–53
Phobias, beta-blockers 24
Phosphoinositide
hydrolysis and calcium homeostasis 258
hydrolysis and stress 561–570
turnover and up-regulated muscarinic receptors 414, 416
Photoreceptor cells, lithium effect on G-protein 733–745
Physostigmine, transfer latency 121, 123
Pimozide, quinine antinociception 354
Piracetam, learning and memory 119
Plasma proteins, melancholia 501–515
Platelets
changes in early puerperium 611
depression 794
Polydipsia, schizophrenia 39, 43
Positron emission tomography
neuroleptics and glucose metabolism in schizophrenia 872–879
sedative drugs and receptor binding 783–789
schizophrenia 449–460
Post-depressive neurotic state, oriental medicines 171
Postnatal depression
biochemical factors 605–615
plasma cortisol 921–932
Post-psychotic depression, imipramine for dysphoric schizophrenic patients 540, 542
Potassium, NGF withdrawal and neuronal degeneration 101
Prefrontal cortex
dopamine and schizophrenia 801, 803, 808, 812, 817
parvalbumin immunoreactivity 333
Premenstrual syndrome 383
Proencephalin gene, expression in chromaffin cells 964
Progesterone, postnatal mood changes 608
Propranolol
apomorphine and amphetamine evoked behaviours 995
efficacy in stress 21
Protein kinase A, proencephalin gene regulation 965, 966
Psychomotor activity
quantitative assessment 27–37
zopiclone 57
Psychosomatic disorders, flupenthixol decanoate 681, 684
Psychotropic drugs, aggression 2
Pyramidal cells, effects of lithium 399
Pyrazoloquinolines, benzodiazepine receptor ligands 767, 775

Quinine, antinociception, effect of dopaminergic agents 351–360
Quinolinic acid, CNS damage in AIDS 148
Quipazine, aggression 858

Rat strains, differential behavioural responses, effect of CRH 549–560
Reaction time, vulnerability to schizophrenia 707
Refractory epilepsies, zonisamide 79–85
REM latency, RS86, depression 311–316
Resident–intruder aggression 850, 855
Retina, effect of lithium 733–745
Rheumatoid arthritis 557
Rhodopsin, activation of G-protein, effect of lithium 738
Ritanserin, effect on neuroleptic-induced akathisia 247–251
Ro15-1781
  anxiety in ethanol withdrawal 89
  SCH23390 binding in brain 783–789
Ro41–7812 760
Ro42–8773 760
RP59037 767
RS86, REM induction in depression 311–316
RU 486, depression 913–920
RU 24969, effect on aggression 855, 858, 862
RU32698 771
RU33697 771
RU33862 765
RU33873 762
RU33894 765
RU33965 759
RU34000 771
RU34030 759
RU34256 765
RU34332 759
RU34363 759
RU39419 765
RU43028 765

S-135 767, 775
Saiko-Ka-Ryukotu-Borei-To, anxiety and depression 172
SCH23390
  binding *in vivo*, effect of sedative drugs 783–789
  gastrointestinal injury 219
  quinine antinociception 354
Schedule IV, 1971 Convention, benzodiazepines 12
Schizophrenia
  cannabis abuse, imipramine 539–547
  dopamine D1 receptor 806–819
  fluid intake patterns 39–44
  indicators of vulnerability 703–715
  mianserin 517–528
  MRI-SPECT 447
  negative symptoms 798
    dopamine D1 receptor 806, 808
    5-HT 816
    modeling 810
    noradrenaline 814
    organic correlates 800
    response to neuroleptics 799
  neuroleptic-induced akathisia 31
  neuroleptics
    brain regional glucose metabolism 871–881
    early serum levels and therapeutic response 891–900
  PET-EEG 449–460
  somatostatin in plasma 203–210
  tardive dystonia and ceruletide 127–134
Scopolamine
  behaviour development in mice 589
  behaviours evoked by apomorphine and amphetamine 223–235
  learning and memory 119–123
Scorpion toxin, calcium currents in neurons 951
Second messenger responses, neuronal cells 253–270
Sedative drugs, effect on receptor binding *in vivo* 783–789
Seizures
  evaluation of antiepileptic drugs 79–85
  neuropeptides in brain 747–753
Senile dementia, neurotransmitter changes 883–890
Sensitization, drugs of abuse, nucleus accumbens 237–246, 1003–1012
Serotonergic transduction, stress 568
Sex hormones, action on the brain 377–388
Simian immunodeficiency virus
  model for neurobehavioural effects of HIV infection 152
  quinolinic acid and neuropathology 148
SKF 38393, effect on gastrointestinal injury 219
SKF 75670C, effect on gastrointestinal injury 219
Sleep
  EEG in depression 793
  REM induction with RS86 in depression 311–316
  zopiclone 59
Sleep–wake schedule disorders 529–537
Social behavioural deficit, 1,3-(trifluoromethyl)phenylpiperazine 362
Social phobia 635–646
  pharmacotherapy 640
Sodium
  effect on field potentials 401
  tetradotoxin-sensitive calcium current 953
Somatostatin, schizophrenia 203–210
Span of Apprehension Test, vulnerability to schizophrenia 706, 709, 712
SPECT, schizophrenia 447
Stress
  adenylate cyclase in brain 586
  agonist-stimulated phosphoinositide hydrolysis in brain 561–570
  beta-blockers 20
  cocaine-induced sensitization 242, 1003, 1006
  gastrointestinal injury, role of dopamine 217–221
  immune functions, AIDS 160
  rat strain differences 555
    clinical significance 557
Substance abuse
  imipramine for dysphoric schizophrenic patients 539–547
  nucleus accumbens 237–246
Substance dependency, adolescents, lithium 289

Substance P, brain regional distribution, effect of chemical convulsants 747–753
Sulpiride
glucose metabolism in schizophrenia 874, 876
quinine antinociception 354
Synaptic transmission, lithium 398
Synergism, carbamazepine + lithium in affective disorders 483–493

Tandospirone, anxiolytic activity 838
Tardive dyskinesia, role of iron 650
Tardive dystonia, ceruletide 127–134
Testosterone, action on noradrenaline neurons 381
Tetrodotoxin-sensitive Ca^{2+} current, in CNS neurons 943–957
Thermoregulation
neuroleptic malignant syndrome 427
anticholinergic drugs 431
nicotine and alcohol 110, 112
Thioridazine, glucose metabolism in schizophrenia 873
Thiothixene, glucose metabolism in schizophrenia 873, 875
Thyroid stimulating hormone, response to TRH in depression, effect of ECT 495–500
Thyrotropin releasing hormone, TSH response in depression, effect of ECT 495–500
Tobacco smoking, topographic EEG 463–482
Tolerance,
1,3-(trifluoromethyl)phenylpiperazine 361–368
Topographic EEG, tobacco smoking 463–482
Transducin, effect of lithium 733–745
Transfectam 960
Transfer latency, drugs affecting learning and memory 117–125
Transferrin, in depression 505
Trazodone
dysthymia 936–939
5-HT_{1A} receptor in brain 343, 346
Triazolam, sleep–wake schedule disorders 534, 536
Tricyclic antidepressants, social phobia 640
m-Trifluoromethylphenylpiperazine
effect in aggression 855, 856, 858, 862
behavioural tolerance 361–368
Tyramine test, postnatal depression 612

U78875 769
Urine volume, schizophrenia 41

Valproate
GABA receptor alterations 571–579
treatment of mania 691–701
Vigilance, nicotine 184
Vimentin, in fibroblasts in Alzheimer's disease 321, 325
Virus-induced behavioural disorders 150
Virus-induced neurological damage 151
Visual cortex, parvalbumin immunoreactivity 333
Vitamin B12, sleep–wake schedule disorders 531, 534, 536

Water intoxication, schizophrenia 39
Withdrawal, alcohol, drug treatment of anxiety 87–93
World Health Organization, regulation of benzodiazepines 9–16

Y-23684 765
Yokukan-San-Ka-Chinpi-Hange, depression and nightmares 174

ZK 91296 762
ZK 93423 762
ZK 93426 762
ZK 112119 762, 764
Zonisamide, refractory epilepsy 79–85
Zopiclone, performance in athletes 55–63